168761-38-4

Upstream product

• 100-46-9 benzylamine 
• 162012-71-7 4,7-dichloro-6-nitro-quinazoline 
• 53449-14-2 7-chloro-6-nitro-4(3H)-quinazolinone 

Downstream Products

• 168761-42-0 4-benzylamino-6-nitro-7-(n-propylamino)quinazoline 
• 168761-43-1 6-nitro-4,7-bis(n-propylamino)quinazoline 
• 168761-39-5 4-benzylamino-7-methylamino-6-nitroquinazoline 
• 168761-41-9 4-benzylamino-7-isopropylamino-6-nitroquinazoline 

Relevant academic research and scientific papers

Structure-activity relationships of 6-nitroquinazolines: Dual-acting compounds with inhibitory activities toward both TNF- α production and T cell proliferation

We synthesized various 6-nitroquinazolines by modifying the structure of compound 1 and evaluated their inhibitory activities toward both TNF-α production and T cell proliferation responses. The presence of the unsubstituted piperazine ring at the C(7)-position was required for both inhibitory activities. In this series of compounds, 5d and 5f, containing the 4-fluorophenyl and 3,4-difluorophenyl moiety, respectively, at the C(4)-position, showed the suppressing effects toward both responses with low cell growth inhibition. Furthermore, the oral administration of these compounds mentioned above at doses of 30 and 100 mg/kg also resulted in significant inhibition of TNF-α production induced by LPS in vivo.

IMIDAZOQUINAZOLINE DERIVATIVES

The present invention relates to imidazoquinazoline derivatives represented by the general formula (I): or pharmacologically acceptable salts thereof. The compounds of the present invention have strong and selective cGMP-specific PDE inhibitory activity and are useful for treating or ameliorating cardiovascular diseases such as thrombosis, angina pectoris, hypertension, arterial sclerosis and the like, as well as asthma and the like